Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: dmkst1 who wrote (1057)	3/3/2000 2:57:00 AM
From: scott_jiminez	Read Replies (1) \| Respond to of 4474

All of the in vivo ARGENT and RAPID studies have been published in either Science or PNAS. These studies show both platforms to work EXCEEDINGLY well...and to be remarkably stable (450+ days for ARGENT for EPO induction in primates). These journals involve, er, somewhat competitive peer review. The ignorance of that poster's claims are a direct reflection the explicit and implicit peer review of Yahoo. (and insofar as the pipeline concern, perhaps an earlier post of mine is apropos siliconinvestor.com